Latest news with #KOSDAQ
Cision Canada
10 hours ago
- Business
- Cision Canada
Parataxis Holdings LLC Announces Definitive Agreement with Bridge Biotherapeutics, Inc. (KOSDAQ: 288330), to Bring Institutionally-Backed, Bitcoin Treasury Company to the South Korean Public Markets:
SEOUL, South Korea and NEW YORK, June 20, 2025 /CNW/ -- Parataxis Holdings LLC ("Parataxis Holdings"), an affiliate of Parataxis Capital Management LLC ("Parataxis Capital" or "PCM"), through Parataxis Korea Fund I LLC and affiliates, has entered into a definitive agreement with Bridge Biotherapeutics, Inc. ("Bridge Bio" or the "Company") to invest KRW 25 billion which would provide Parataxis Holdings a controlling interest in the Company (the "Transaction"). Following the closing of the Transaction, the Company intends to change its corporate name to Parataxis Korea and remain listed on the KOSDAQ. The Transaction is subject to customary closing conditions, including approval by the Company's shareholders. The Transaction would result in the creation of a Bitcoin-native treasury platform in the South Korean public markets that is anchored by institutional investors with significant experience in digital asset investments. As part of the Transaction, Edward Chin, Founder and CEO of Parataxis Holdings, and Co-Founder & CEO of Parataxis Capital, will be joining the Board of Directors of the Company. Andrew Kim, Partner at Parataxis Capital, will assume the role of CEO of the Company and will also join the Board of Directors. James Jungkue Lee, Co-founder of Bridge Bio will continue to lead the core biotech business and serve on the Company's Board of Directors. "Inspired by the growing interest in BTC treasury strategies seen in companies like Strategy in the US and Metaplanet in Japan, we believe institutional interest in this space is increasing globally. We see South Korea as an important market in the evolution of BTC adoption. Our intent is to support institutional access to BTC exposure while emphasizing sound corporate governance and disciplined capital management," said Andrew Kim. "We are incredibly excited to create the first BTC treasury company in South Korea backed by an institutional-grade platform. Given the strategic nature of BTC on the global stage and its finite supply, we believe that building and growing a company like Parataxis Korea and accumulating a BTC treasury will benefit our shareholders as well as the country over the long run," said Edward Chin of Parataxis Holdings. Along with the contemplated Transaction, Parataxis Holdings is closing another fund with substantially the same strategy, and is in the process of launching additional fund vehicles. Parataxis Holdings expects to announce additional details regarding the Transaction after conducting a shareholder meeting expected in August. Shin & Kim LLC, is acting as legal advisor to Parataxis Korea Fund I LLC in the Transaction. Deloitte is acting as financial advisor to Parataxis Korea Fund I LLC in the Transaction. About Parataxis Capital Management and Parataxis Holdings Parataxis Capital Management is a multi-strategy investment firm focused on the digital asset sector. PCM was founded in 2019 and manages multiple commingled hedge fund vehicles and provides sub-advisory services for institutional allocators, family offices, fund-of-funds and high-net worth individuals. Parataxis Holdings is an affiliate of PCM and focused on BTC treasury and other digital asset investment opportunities. Both firms are headquartered in New York City. About Bridge Biotherapeutics Bridge Biotherapeutics, Inc. is a clinical stage biotech company engaged in the development and commercialization of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The Company was founded in 2015 and was listed on the KOSDAQ in 2019. Bridge Bio is headquartered in Seongnam, South Korea. Forward-Looking Statements: This press release contains forward-looking statements, including but not limited to those relating to the proposed transaction, potential business combination, and the anticipated use of proceeds. These statements are based on current expectations and projections and are subject to risks and uncertainties that could cause actual results to differ materially. There is no assurance that the transaction described herein will be completed as contemplated, or at all. The Company assumes no obligation to revise or update any forward-looking statements after the date of this release, except as required by applicable law. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction, and should not be interpreted as investment advice or a recommendation regarding any investment decision. Investing involves inherent risks, including the potential loss of principal. Any investment decision must be made solely at the discretion and responsibility of the investor. No representation or warranty, express or implied, is made by the Company with respect to the accuracy of any information contained herein or the achievement of any investment returns or financial results.
Yahoo
2 days ago
- Business
- Yahoo
Asian Growth Companies With High Insider Ownership In June 2025
As the Asian markets navigate a landscape marked by geopolitical tensions and trade negotiations, investors are increasingly focusing on companies with strong fundamentals and strategic insider ownership. In this context, growth companies in Asia with high insider ownership present an intriguing opportunity, as they often reflect a commitment to long-term success and alignment of interests between management and shareholders. Name Insider Ownership Earnings Growth Zhejiang Leapmotor Technology (SEHK:9863) 15.6% 59.9% Vuno (KOSDAQ:A338220) 15.6% 109.8% Techwing (KOSDAQ:A089030) 18.8% 68% Suzhou Sunmun Technology (SZSE:300522) 35.4% 77.7% Sineng ElectricLtd (SZSE:300827) 36% 26.9% Shanghai Huace Navigation Technology (SZSE:300627) 24.3% 23.5% Samyang Foods (KOSE:A003230) 11.7% 24.3% M31 Technology (TPEX:6643) 30.8% 63.4% Laopu Gold (SEHK:6181) 35.5% 40.3% Fulin Precision (SZSE:300432) 13.6% 43% Click here to see the full list of 606 stocks from our Fast Growing Asian Companies With High Insider Ownership screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Growth Rating: ★★★★★★ Overview: Sineng Electric Co., Ltd. specializes in the research, development, manufacture, maintenance, and trading of power electronic products both in China and internationally, with a market cap of approximately CN¥10.59 billion. Operations: Sineng Electric Co., Ltd. generates revenue through its operations in the research, development, manufacture, maintenance, and trading of power electronic products across domestic and international markets. Insider Ownership: 36% Revenue Growth Forecast: 22% p.a. Sineng Electric Ltd. demonstrates strong growth potential with earnings forecasted to grow significantly over the next three years, surpassing the broader Chinese market. The company recently reported a notable increase in net income and revenue for Q1 2025, alongside a strategic share buyback plan of CNY 49.99 million. Trading at a favorable price-to-earnings ratio compared to industry peers, Sineng Electric also approved a cash dividend increase, reflecting robust financial health and shareholder value focus. Take a closer look at Sineng ElectricLtd's potential here in our earnings growth report. The analysis detailed in our Sineng ElectricLtd valuation report hints at an deflated share price compared to its estimated value. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Chengdu RML Technology Co., Ltd. specializes in the research, development, manufacturing, testing, and sale of millimeter-wave microsystems, with a market cap of CN¥12.31 billion. Operations: Chengdu RML Technology generates its revenue primarily from the research, development, manufacturing, testing, and sale of millimeter-wave microsystems. Insider Ownership: 28.9% Revenue Growth Forecast: 17.2% p.a. Chengdu RML Technology is poised for growth with earnings expected to rise significantly over the next three years, outpacing the Chinese market. Despite a recent drop in Q1 2025 revenue and net income, its price-to-earnings ratio remains attractive compared to industry peers. The company recently approved a cash dividend plan at its AGM, indicating a commitment to shareholder returns. However, share price volatility and limited insider trading activity are considerations for potential investors. Get an in-depth perspective on Chengdu RML Technology's performance by reading our analyst estimates report here. According our valuation report, there's an indication that Chengdu RML Technology's share price might be on the expensive side. Simply Wall St Growth Rating: ★★★★☆☆ Overview: SAKURA Internet Inc. offers cloud computing services in Japan and has a market cap of ¥168.81 billion. Operations: The company's revenue is primarily derived from its Internet Infrastructure Business, which generated ¥31.41 billion. Insider Ownership: 18.1% Revenue Growth Forecast: 13.1% p.a. SAKURA Internet shows promising growth potential with earnings forecasted to increase significantly over the next three years, surpassing Japan's market average. The company recently confirmed its fiscal year guidance, expecting net sales of ¥40.4 billion and operating profit of ¥3.8 billion. Despite a volatile share price and low return on equity forecast, SAKURA Internet increased its dividend payout, reflecting confidence in future performance and commitment to shareholder value amidst stable insider ownership levels. Navigate through the intricacies of SAKURA Internet with our comprehensive analyst estimates report here. The analysis detailed in our SAKURA Internet valuation report hints at an inflated share price compared to its estimated value. Discover the full array of 606 Fast Growing Asian Companies With High Insider Ownership right here. Interested In Other Possibilities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include SZSE:300827 SZSE:301050 and TSE:3778. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
June 2025's Leading Asian Growth Stocks With High Insider Ownership
In June 2025, Asian markets have been navigating a complex economic landscape, with geopolitical tensions and trade negotiations influencing investor sentiment. Despite these challenges, the region continues to offer promising opportunities for growth investors, particularly in companies where high insider ownership aligns management's interests with those of shareholders. Name Insider Ownership Earnings Growth Zhejiang Leapmotor Technology (SEHK:9863) 15.6% 59.9% Vuno (KOSDAQ:A338220) 15.6% 109.8% Suzhou Sunmun Technology (SZSE:300522) 35.4% 77.7% Shanghai Huace Navigation Technology (SZSE:300627) 24.3% 23.5% Schooinc (TSE:264A) 30.6% 68.9% Samyang Foods (KOSE:A003230) 11.7% 24.3% Oscotec (KOSDAQ:A039200) 21.1% 94.4% M31 Technology (TPEX:6643) 30.8% 63.4% Laopu Gold (SEHK:6181) 35.5% 40.3% Fulin Precision (SZSE:300432) 13.6% 43% Click here to see the full list of 609 stocks from our Fast Growing Asian Companies With High Insider Ownership screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Kingdee International Software Group Company Limited is an investment holding company that operates in the enterprise resource planning sector, with a market capitalization of approximately HK$50.46 billion. Operations: The company's revenue segments include CN¥1.15 billion from its ERP Business and CN¥5.11 billion from its Cloud Services Business. Insider Ownership: 19.9% Revenue Growth Forecast: 14.2% p.a. Kingdee International Software Group is poised for growth with forecasted revenue expansion of 14.2% annually, outpacing the Hong Kong market's 8.2%. While recent insider activity shows more purchases than sales, volumes aren't substantial. Analysts expect profitability within three years and anticipate a 23.7% stock price increase. Despite a net loss reduction to CNY 142.07 million in 2024 from CNY 209.89 million previously, the company trades significantly below its estimated fair value, suggesting potential upside. Take a closer look at Kingdee International Software Group's potential here in our earnings growth report. In light of our recent valuation report, it seems possible that Kingdee International Software Group is trading behind its estimated value. Simply Wall St Growth Rating: ★★★★★☆ Overview: Jinlei Technology Co., Ltd. develops, produces, and sells wind turbine spindles as well as various castings and forgings both in China and internationally, with a market cap of CN¥6.81 billion. Operations: Jinlei Technology generates revenue through the development, production, and sale of wind turbine spindles, along with a variety of castings and forgings for both domestic and international markets. Insider Ownership: 34.9% Revenue Growth Forecast: 21% p.a. Jinlei Technology is experiencing robust growth, with earnings projected to rise 36.42% annually, surpassing the Chinese market's average. Despite a low forecasted return on equity of 8.5%, its price-to-earnings ratio of 34.2x remains attractive compared to the market average of 38.3x. Recent financials show significant sales and net income increases in Q1 2025, yet profit margins have declined from the previous year, potentially impacting long-term sustainability despite high insider ownership stability. Click here and access our complete growth analysis report to understand the dynamics of Jinlei Technology. According our valuation report, there's an indication that Jinlei Technology's share price might be on the expensive side. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Japan Elevator Service Holdings Co., Ltd. specializes in the repair, maintenance, and modernization of elevators and escalators in Japan, with a market cap of ¥357.56 billion. Operations: The company's revenue primarily comes from its Maintenance Business, generating ¥49.38 billion. Insider Ownership: 21.3% Revenue Growth Forecast: 11.2% p.a. Japan Elevator Service Holdings demonstrates solid growth prospects, with earnings projected to increase by 18% annually, outpacing the Japanese market average. Despite slower revenue growth at 11.2%, it remains above the market's 3.8%. Recent announcements include a dividend increase to ¥31 per share and fiscal year guidance projecting net sales of ¥55 billion and operating profit of ¥10 billion. High return on equity forecasts bolster its position, though insider trading activity remains minimal recently. Unlock comprehensive insights into our analysis of Japan Elevator Service HoldingsLtd stock in this growth report. The valuation report we've compiled suggests that Japan Elevator Service HoldingsLtd's current price could be inflated. Investigate our full lineup of 609 Fast Growing Asian Companies With High Insider Ownership right here. Ready For A Different Approach? Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include SEHK:268 SZSE:300443 and TSE:6544. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información
Yahoo
4 days ago
- Business
- Yahoo
3 Asian Growth Companies With High Insider Ownership Expecting Up To 30% Revenue Growth
As geopolitical tensions rise and trade negotiations between major economies continue to evolve, Asia's markets have shown resilience amidst global uncertainties. In this environment, growth companies with high insider ownership can be particularly appealing, as they often indicate strong internal confidence and alignment with shareholder interests. Name Insider Ownership Earnings Growth Vuno (KOSDAQ:A338220) 15.6% 109.8% Techwing (KOSDAQ:A089030) 18.8% 68% Suzhou Sunmun Technology (SZSE:300522) 35.4% 77.7% Sineng ElectricLtd (SZSE:300827) 36% 26.9% Shanghai Huace Navigation Technology (SZSE:300627) 24.3% 23.5% Samyang Foods (KOSE:A003230) 11.7% 24.3% Oscotec (KOSDAQ:A039200) 21.1% 94.4% Nanya New Material TechnologyLtd (SHSE:688519) 11% 63.3% Laopu Gold (SEHK:6181) 35.5% 40.3% Fulin Precision (SZSE:300432) 13.6% 43% Click here to see the full list of 611 stocks from our Fast Growing Asian Companies With High Insider Ownership screener. Let's dive into some prime choices out of the screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: DPC Dash Ltd, along with its subsidiaries, operates a chain of fast-food restaurants in the People's Republic of China and has a market cap of HK$12.92 billion. Operations: The company's revenue primarily comes from its fast-food restaurant operations in the People's Republic of China, generating CN¥4.31 billion. Insider Ownership: 37.7% Revenue Growth Forecast: 21.9% p.a. DPC Dash's insider ownership is noteworthy, with more shares bought than sold recently. The company has turned profitable, reporting a net income of CNY 55.2 million for 2024, and earnings are expected to grow significantly over the next three years. Revenue growth is forecast at 21.9% annually, outpacing the Hong Kong market. Despite recent executive changes, including Mr. Weiking Ng's appointment as a non-executive director, analysts expect the stock price to rise by 25.4%. Click here and access our complete growth analysis report to understand the dynamics of DPC Dash. The analysis detailed in our DPC Dash valuation report hints at an inflated share price compared to its estimated value. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Smoore International Holdings Limited is an investment holding company that provides vaping technology solutions, with a market cap of HK$122.49 billion. Operations: The company's revenue primarily comes from the sale of APV and vaping devices and components, totaling CN¥11.80 billion. Insider Ownership: 39.7% Revenue Growth Forecast: 11.7% p.a. Smoore International Holdings has seen significant insider buying recently, reflecting confidence in its growth prospects. Earnings are expected to grow at 23.4% annually, outpacing the Hong Kong market's growth rate of 10.6%. However, revenue growth is forecasted at a slower pace of 11.7% per year. The company declared a final dividend of HK$0.05 per share for 2024 despite reporting lower net income (CNY1.30 billion) compared to the previous year (CNY1.65 billion). Click here to discover the nuances of Smoore International Holdings with our detailed analytical future growth report. According our valuation report, there's an indication that Smoore International Holdings' share price might be on the expensive side. Simply Wall St Growth Rating: ★★★★★☆ Overview: SolaX Power Network Technology (Zhejiang) Co., Ltd. (ticker: SHSE:688717) is a company engaged in the development and production of solar energy products, with a market cap of CN¥9.12 billion. Operations: The company's revenue primarily comes from its Electronic Components & Parts segment, which generated CN¥3.19 billion. Insider Ownership: 35.1% Revenue Growth Forecast: 30.6% p.a. SolaX Power Network Technology (Zhejiang) demonstrates strong growth potential with expected annual earnings growth of 62.5%, significantly outpacing the Chinese market. Revenue is also forecasted to increase by 30.6% annually, surpassing market averages. Recent product innovations, such as the SolaXCloud Security Strategy, align with stringent cybersecurity standards and enhance its competitive edge in energy management solutions. Despite these positives, profit margins have decreased from last year, and insider trading data is unavailable for recent months. Take a closer look at SolaX Power Network Technology (Zhejiang)'s potential here in our earnings growth report. Our valuation report unveils the possibility SolaX Power Network Technology (Zhejiang)'s shares may be trading at a discount. Gain an insight into the universe of 611 Fast Growing Asian Companies With High Insider Ownership by clicking here. Searching for a Fresh Perspective? Uncover 16 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include SEHK:1405 SEHK:6969 and SHSE:688717. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 days ago
- Health
- Business Wire
D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health
GYEONGGI-DO, South Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company developing breakthrough treatments for liver and metabolic diseases, today announced positive results from DD01-DN-02 study, an ongoing 48-week Phase 2 trial designed to evaluate the efficacy and safety of DD01 (a once-weekly dual GLP1/glucagon receptor agonist) in 67 overweight/obese subjects with MASH. DD01 treatment was initiated with two weeks of dosing at 20 mg, followed by the 40mg once-weekly maintenance dose. Results of a planned 12-week assessment of safety and efficacy revealed DD01 was well tolerated, and the study's primary endpoint was met. Following a 1:1 randomization of 40mg DD01 and placebo, 75.8% of subjects treated with DD01 achieved at least a 30% reduction in liver fat, 72.7% of subjects achieved greater than 50% reduction in liver fat, and 57.6% of subjects achieved greater than 70% liver fat reduction (in each case, with p < 0.0001). DD01 achieved a mean reduction of liver fat content of 62.3% vs 8.3% for placebo at 12 weeks of treatment, and 48.5% of DD01 subjects achieved normalization of liver fat fraction (defined as liver fat fraction of 5% or less by MRI-PDFF). No placebo subject achieved normalization. Treatment related reductions in Non-invasive markers of MASH progression were used to evaluate subjects at baseline and after 12 weeks of treatment. DD01 treatment was associated with statistically significant improvements in liver stiffness (MRE), pro-C3 levels, and ELF score. Additional Endpoints Twelve-week weight loss data were encouraging. While placebo-treated subjects had no significant weight loss, 42.4% of DD01-treated subjects achieving a greater than 5% reduction in weight. Also encouraging were the results of HbA1c testing. While the study population was not selected to be diabetic, following 12 weeks of DD01 treatment, HbA1c reduction was statistically significant compared to placebo. Safety Results DD01 was well tolerated. Gastrointestinal (GI) side effects were most common, generally mild to moderate, but transient and manageable. To date, only 3 subjects have discontinued treatment due to GI-related adverse events. Implications Seulki Lee, Ph.D., President and Chief Executive Officer of D&D Pharmatech, stated, 'We have remarkably positive results for DD01 after only 12 weeks of treatment in MASH. The magnitude of improvements is equivalent to what has been achieved only after longer-term treatment with FGF and GLP-1 based drugs already validated with histology data in MASH.' 'Considering the combination of liver and metabolic benefits and the favorable tolerability profile, DD01 has the potential to provide patients and physicians with a MASH treatment that is easy to manage, encourages weight loss and is diabetes friendly.' Mazen Noureddin, MD, MHSc, Professor of Medicine at Houston Methodist Hospital; Co-Chairman of the Board, Summit & Pinnacle Clinical Research; Director, Houston Research Institutes, commented, 'The degree of liver fat reduction with DD01 is striking, with nearly three-quarters of patients achieving at least a 30% reduction and almost half reaching normalization within just 12 weeks. The observed improvement in liver stiffness by MRE, though early, adds further support to the biological activity of this dual GLP-1/glucagon approach, which is designed to act directly on the liver.' 'These consistent MRI-PDFF results provide strong confidence that DD01 has the potential to meet both key regulatory endpoints - MASH resolution and fibrosis improvement - as the program advances. Coupled with favorable metabolic effects and a very low treatment discontinuation rate, DD01 is emerging as a well-differentiated and promising therapy, both within its class and compared to other potent agents in development.' Additional data will be presented at upcoming medical meetings. About DD01 DD01 is a once-weekly dual GLP1/glucagon receptor agonist with a half-life of 7-8 days in obese/overweight patients with T2D and MASLD. Following a Phase 1 study that showed DD01 rapidly reduced liver steatosis, improved glucose tolerance, and encouraged weight loss in obese subjects with MASLD and type 2 diabetes, FDA granted DD01 Fast Track Designation for the treatment of MASH. Current Phase 2 results confirm and extend these findings revealing additional benefits in patients with MASH. The effect of DD01 is consistent with its dual-agonist pharmacology. Clinical results show the effects of DD01 are remarkably rapid. DD01 achieves robust results rapidly and with tolerability comparable to other validated MASH treatments. The GLP1:glucagon potency ratio for DD01 is 11:1. GLP-1R potency is likely an important driver in glucose management for diabetic patients and in weight loss. Importantly, with this ratio, DD01 is clearly also a potent glucagon receptor agonist. Substantial liver fat reduction was observed after only 4 weeks in obese subjects with MASLD (Phase 1). Liver fat reduction by DD01 is clearly not secondary to weight loss at these early timepoints, differentiating it mechanistically from the pure incretin approach. In terms of the balance between efficacy and tolerability, the pharmacokinetics of DD01 are also unique. Good tolerability at clinically active doses is likely aided by very slow absorption (tmax = 6 days) and a long half-life (7-8 days), features which make the onset and rise in DD01 exposure gradual. Peaks associated with poor tolerability and troughs associated with diminished efficacy are avoided. As a result, the need for a lengthy titration period is eliminated and therapeutic levels are reached rapidly. A key differentiator for DD01 is the balanced constellation of clinical benefits afforded by a unique pharmacologic and pharmacodynamic signature. Current data suggest DD01 has the necessary attributes to offer patients and physicians a treatment that is easy to use, supports both liver and metabolic health. About the DD01-DN-02 Trial With the support of staff at Summit Clinical Research, the study investigators, and the study participants, the DD01-DN-02 study is fully enrolled and currently ongoing at 12 centers in the U.S. Baseline characteristics were well balanced between both treatment groups with nearly identical mean liver fat fractions (overall mean of 20.7%) and similar body weight (overall mean 99.4 kg) at baseline. Treatment is ongoing and the study includes non-invasive and histologic assessments of MASH resolution and change in fibrosis at 48 weeks. More information about the study is available at under the identifier NCT06410924. About D&D Pharmatech D&D Pharmatech is a clinical-stage biopharmaceutical company focused on developing revolutionary medicines for patients with a number of metabolic, fibrotic, and neurodegenerative diseases. DD01 and TLY012 are in development for fibrotic liver disease (MASH and cirrhosis). TLY012 has completed IND-enabling studies and has been shown to slow and even reverse established fibrosis in models of liver cirrhosis, chronic pancreatitis, and systemic scleroderma. Two products are in development for neurodegenerative diseases. NLY02 is a small molecule BBB penetrating kinase inhibitor targeting glial activation. It is a potent inhibitor of neurodegeneration. NLY01 is also a potent inhibitor of glial activation. It acts through the incretin pathway to reduce neuronal loss and slow functional decline in models of Parkinson's, Alzheimer's, and multiple sclerosis. In a recently completed Phase 2 study conducted in >250 Parkinson's patients, 36-week of treatment with NLY01 resulted in a significant reduction in motor function decline (UPDRS III) in ~1/3 of trial subjects. NLY01 appeared to slow the progressive decline in motor function in newly diagnosed patients who were young (<60) and treatment naïve. D&D Pharmatech's ORALINK technology allows efficient oral uptake of therapeutic peptides. In partnership with Metsera, the company is developing orally active incretin-based peptide drugs for obesity.
